Børresen-Dale AL - Search Results

1

Recurrent fallopian tube carcinoma: TP53 mutation and clinical course.

Hellström AC, Blegen H, Malec M, Silfverswärd C, Lystad S, Børresen-Dale AL, Auer G. Hellström AC, et al. Int J Gynecol Pathol. 2000 Apr;19(2):145-51. doi: 10.1097/00004347-200004000-00008. Int J Gynecol Pathol. 2000. PMID: 10782411

2

Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.

Zelada-Hedman M, Børresen-Dale AL, Claro A, Chen J, Skoog L, Lindblom A. Zelada-Hedman M, et al. Br J Cancer. 1997;75(8):1201-4. doi: 10.1038/bjc.1997.205. Br J Cancer. 1997. PMID: 9099970 Free PMC article.

3

Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction.

Bjørheim J, Lystad S, Lindblom A, Kressner U, Westring S, Wahlberg S, Lindmark G, Gaudernack G, Ekstrøm P, Røe J, Thilly WG, Børresen-Dale AL. Bjørheim J, et al. Mutat Res. 1998 Jul 17;403(1-2):103-12. doi: 10.1016/s0027-5107(98)00057-8. Mutat Res. 1998. PMID: 9726011

4

TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.

Högmo A, Börresen-Dale AL, Blegen H, Lindholm J, Kuylenstierna R, Auer G, Munck-Wikland E. Högmo A, et al. Anticancer Res. 1999 Jul-Aug;19(4C):3433-8. Anticancer Res. 1999. PMID: 10629631

5

TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.

Skomedal H, Kristensen GB, Abeler VM, Børresen-Dale AL, Tropé C, Holm R. Skomedal H, et al. J Pathol. 1997 Feb;181(2):158-65. doi: 10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8. J Pathol. 1997. PMID: 9120719

6

A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.

Zelada-Hedman M, Wasteson Arver B, Claro A, Chen J, Werelius B, Kok H, Sandelin K, Håkansson S, Andersen TI, Borg A, Børresen Dale AL, Lindblom A. Zelada-Hedman M, et al. Cancer Res. 1997 Jun 15;57(12):2474-7. Cancer Res. 1997. PMID: 9192828

7

TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.

Skomedal H, Kristensen GB, Nesland JM, Børresen-Dale AL, Tropé C, Holm R. Skomedal H, et al. J Pathol. 1999 Apr;187(5):556-62. doi: 10.1002/(SICI)1096-9896(199904)187:5<556::AID-PATH294>3.0.CO;2-Y. J Pathol. 1999. PMID: 10398121

8

BRCA1 screening in patients with a family history of breast or ovarian cancer.

Arver B, Claro A, Langerød A, Børresen-Dale AL, Lindblom A. Arver B, et al. Genet Test. 1999;3(2):223-6. doi: 10.1089/gte.1999.3.223. Genet Test. 1999. PMID: 10464672

9

Low frequency of E-cadherin alterations in familial breast cancer.

Salahshor S, Haixin L, Huo H, Kristensen VN, Loman N, Sjöberg-Margolin S, Borg A, Børresen-Dale AL, Vorechovsky I, Lindblom A. Salahshor S, et al. Breast Cancer Res. 2001;3(3):199-207. doi: 10.1186/bcr295. Epub 2001 Mar 9. Breast Cancer Res. 2001. PMID: 11305955 Free PMC article.

10

TP53 and breast cancer.

Børresen-Dale AL. Børresen-Dale AL. Hum Mutat. 2003 Mar;21(3):292-300. doi: 10.1002/humu.10174. Hum Mutat. 2003. PMID: 12619115 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

508 results

Search Page